THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Charles River ends acquisition bid

Shareholder reaction scrubs $1.6b purchase of Chinese drug firm

Charles River CEO James C. Foster had pushed for the deal. Charles River CEO James C. Foster had pushed for the deal.
By Todd Wallack
Globe Staff / July 31, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Facing a revolt from angry shareholders, Charles River Laboratories International Inc. has scuttled plans to buy a Chinese drug research firm for $1.6 billion, a deal that would have been the biggest in the Wilmington company’s 63-year history. (Full article: 688 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass